Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, MD, USA.
Center on Compulsive Behaviors, National Institutes of Health, Bethesda, MD, USA.
Transl Psychiatry. 2020 Feb 19;10(1):71. doi: 10.1038/s41398-020-0756-3.
As perspectives on cannabis continue to shift, understanding the physiological and behavioral effects of cannabis use is of paramount importance. Previous data suggest that cannabis use influences food intake, appetite, and metabolism, yet human research in this regard remains scant. The present study investigated the effects of cannabis administration, via different routes, on peripheral concentrations of appetitive and metabolic hormones in a sample of cannabis users. This was a randomized, crossover, double-blind, placebo-controlled study. Twenty participants underwent four experimental sessions during which oral cannabis, smoked cannabis, vaporized cannabis, or placebo was administered. Active compounds contained 6.9 ± 0.95% (~50.6 mg) ∆9-tetrahydrocannabinol (THC). Repeated blood samples were obtained, and the following endocrine markers were measured: total ghrelin, acyl-ghrelin, leptin, glucagon-like peptide-1 (GLP-1), and insulin. Results showed a significant drug main effect (p = 0.001), as well as a significant drug × time-point interaction effect (p = 0.01) on insulin. The spike in blood insulin concentrations observed under the placebo condition (probably due to the intake of brownie) was blunted by cannabis administration. A significant drug main effect (p = 0.001), as well as a trend-level drug × time-point interaction effect (p = 0.08) was also detected for GLP-1, suggesting that GLP-1 concentrations were lower under cannabis, compared to the placebo condition. Finally, a significant drug main effect (p = 0.01) was found for total ghrelin, suggesting that total ghrelin concentrations during the oral cannabis session were higher than the smoked and vaporized cannabis sessions. In conclusion, cannabis administration in this study modulated blood concentrations of some appetitive and metabolic hormones, chiefly insulin, in cannabis users. Understanding the mechanisms underpinning these effects may provide additional information on the cross-talk between cannabinoids and physiological pathways related to appetite and metabolism.
随着对大麻的看法不断变化,了解大麻使用对生理和行为的影响至关重要。先前的数据表明,大麻的使用会影响食欲、新陈代谢和食物摄入,但这方面的人体研究仍然很少。本研究调查了大麻通过不同途径给药对大麻使用者外周食欲和代谢激素浓度的影响。这是一项随机、交叉、双盲、安慰剂对照研究。20 名参与者接受了四次实验,在实验中分别给予口服大麻、吸食大麻、汽化大麻或安慰剂。活性化合物含有 6.9±0.95%(~50.6mg)∆9-四氢大麻酚(THC)。反复采集血样,测量以下内分泌标志物:总胃饥饿素、酰基胃饥饿素、瘦素、胰高血糖素样肽-1(GLP-1)和胰岛素。结果显示,胰岛素存在显著的药物主效应(p=0.001)和药物-时间点交互效应(p=0.01)。在安慰剂条件下观察到的胰岛素浓度升高(可能是由于摄入布朗尼)被大麻给药所抑制。GLP-1 也显示出显著的药物主效应(p=0.001)和趋势水平的药物-时间点交互效应(p=0.08),表明与安慰剂相比,大麻条件下 GLP-1 浓度较低。最后,总胃饥饿素显示出显著的药物主效应(p=0.01),表明口服大麻时总胃饥饿素浓度高于吸食大麻和汽化大麻时的浓度。总之,本研究中大麻给药调节了大麻使用者血液中一些食欲和代谢激素的浓度,主要是胰岛素。了解这些作用背后的机制可能会提供有关大麻素与食欲和新陈代谢相关生理途径之间相互作用的更多信息。